138 related articles for article (PubMed ID: 23861152)
21. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
22. [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Qian W; Zhu G; Ji Q; Guo Y; Wang Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):217-22. PubMed ID: 24785284
[TBL] [Abstract][Full Text] [Related]
23. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.
Zhang H; Kim S; Chen Z; Nannapaneni S; Chen AY; Moore CE; Sica G; Mosunjac M; Nguyen MLT; D'Souza G; Carey TE; Peterson LA; McHugh JB; Graham M; Komarck CM; Wolf GT; Walline HM; Bellile E; Riddell J; Pai SI; Sidransky D; Westra WH; William WN; Lee JJ; El-Naggar AK; Ferris RL; Seethala R; Grandis JR; Chen ZG; Saba NF; Shin DM;
Head Neck; 2017 Dec; 39(12):2433-2443. PubMed ID: 28945296
[TBL] [Abstract][Full Text] [Related]
24. Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Harris BN; Pipkorn P; Nguyen KNB; Jackson RS; Rao S; Moore MG; Farwell DG; Bewley AF
JAMA Otolaryngol Head Neck Surg; 2019 Feb; 145(2):153-158. PubMed ID: 30570645
[TBL] [Abstract][Full Text] [Related]
25. Influence of HPV-status on survival of patients with tonsillar carcinomas (TSCC) treated by CO
Hoffmann M; Quabius ES; Tribius S; Gebhardt S; Görögh T; Hedderich J; Huber K; Dunst J; Ambrosch P
Cancer Lett; 2018 Jan; 413():59-68. PubMed ID: 29100961
[TBL] [Abstract][Full Text] [Related]
26. Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression.
Alterio D; Marvaso G; Maffini F; Gandini S; Chiocca S; Ferrari A; Preda L; Rocca MC; Lepanto D; Fodor C; Volpe S; Dicuonzo S; Laudati A; Giugliano G; Ansarin M; Jereczek-Fossa BA
Med Oncol; 2017 Jun; 34(6):107. PubMed ID: 28452036
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
28. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
Park MJ; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2018 Mar; 92():69-76. PubMed ID: 29428866
[TBL] [Abstract][Full Text] [Related]
30. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
Rades D; Strojan P; Seidl D; Janssen S; Bajrovic A; Kazic N; Hakim SG; Wollenberg B; Schild SE
J Craniomaxillofac Surg; 2016 Sep; 44(9):1436-40. PubMed ID: 27499514
[TBL] [Abstract][Full Text] [Related]
31. PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck.
Snietura M; Jaworska M; Mlynarczyk-Liszka J; Goraj-Zajac A; Piglowski W; Lange D; Wozniak G; Nowara E; Suwinski R
PLoS One; 2012; 7(3):e33396. PubMed ID: 22413021
[TBL] [Abstract][Full Text] [Related]
32. Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma.
Dixon PR; Au M; Hosni A; Perez-Ordonez B; Weinreb I; Xu W; Song Y; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
Head Neck; 2016 Sep; 38(9):1347-53. PubMed ID: 27002481
[TBL] [Abstract][Full Text] [Related]
33. Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?
Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Karner K; Strojan P; Schild SE
Oral Oncol; 2016 Aug; 59():67-72. PubMed ID: 27424184
[TBL] [Abstract][Full Text] [Related]
34. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors.
Schäfer U; Micke O; Müller SB; Schüller P; Willich N
Strahlenther Onkol; 2003 Aug; 179(8):527-34. PubMed ID: 14509951
[TBL] [Abstract][Full Text] [Related]
35. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity.
Rades D; Ulbricht T; Hakim SG; Schild SE
Strahlenther Onkol; 2012 Jan; 188(1):42-8. PubMed ID: 22194029
[TBL] [Abstract][Full Text] [Related]
37. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.
Rubin Grandis J; Melhem MF; Gooding WE; Day R; Holst VA; Wagener MM; Drenning SD; Tweardy DJ
J Natl Cancer Inst; 1998 Jun; 90(11):824-32. PubMed ID: 9625170
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.
de Miguel-Luken MJ; Chaves-Conde M; Quintana B; Menoyo A; Tirado I; de Miguel-Luken V; Pachón J; Chinchón D; Suarez V; Carnero A
Oncotarget; 2016 May; 7(22):31723-37. PubMed ID: 27166270
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and immunohistochemical evaluation of oral and oropharyngeal squamous cell carcinoma in Chilean population.
Rivera C; González-Arriagada WA; Loyola-Brambilla M; de Almeida OP; Coletta RD; Venegas B
Int J Clin Exp Pathol; 2014; 7(9):5968-77. PubMed ID: 25337241
[TBL] [Abstract][Full Text] [Related]
40. Parotid and cervical nodal status predict prognosis for patients with head and neck metastatic cutaneous squamous cell carcinoma.
Ch'ng S; Maitra A; Allison RS; Chaplin JM; Gregor RT; Lea R; Tan ST
J Surg Oncol; 2008 Aug; 98(2):101-5. PubMed ID: 18523982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
